研究疾病:
|
慢性自发性荨麻疹
|
研究疾病代码:
|
|
Target disease:
|
chronic spontaneous urticaria
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
其它
Others
|
研究目的:
|
本项目基于本课题组前期研究基础,以 CSU 为研究对象,运用多模态 MRI成像技术,从“脑结构-功能网络-神经代谢”多维度,探索针刺“从心论治”CSU的即刻中枢效应机制、累积中枢效应机制及对小脑神经代谢的影响机制,验证我们提出的假说:针刺通过特定的中枢止痒效应网络,影响小脑的神经代谢及“小脑-奖赏-体感运动”环路功能,进而达到瘙痒的脑调控效应。通过以上研究进一步明确针刺的中枢止痒效应机制,以此阐释“诸痛痒疮,皆属于心”及其“皮部-经络-脏腑(脑)”模式,以及针刺“从心论治”的深刻理论内涵。
|
Objectives of Study:
|
This project is based on the previous research of our research group, taking CSU as the research object, using multi-modal MRI imaging technology, from the multiple dimensions of "brain structure function network neurometabolism", explores the immediate central effect mechanism, cumulative central effect mechanism and the influence mechanism on cerebellar neurometabolism of acupuncture "treating from the heart" CSU, and verifies our hypothesis that acupuncture affects cerebellar neurometabolism and "cerebellar reward somatosensory motor" loop through specific central antipruritic effect network Function, and then achieve the brain regulatory effect of pruritus. Through the above studies, the mechanism of central antipruritic effect of acupuncture is further clarified, so as to explain the profound theoretical connotation of "all pain and itching sores belong to the heart" and its "skin meridian viscera (brain)" model, as well as acupuncture "treatment from the heart".
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
1. 年龄18-60岁之间,性别不限。
2. 符合慢性自发性荨麻疹诊断标准:风团每天发作或间歇发作,每次持续时间不超过24小时,持续时间>6周。
3. 尽管在使用H1抗组胺药, 但在入组前至少连续6周出现风团与瘙痒。
4. 7天荨麻疹活动性评分(UAS)≥16分,每周瘙痒评分≥8分。
5. 随机分组前一周患者日记卡完整。
6. 签署知情同意书,自愿并同意完成本临床研究的各步骤。
|
Inclusion criteria
|
1. The age is between 18-60 years old, regardless of gender.
2. Accord with the diagnostic criteria of chronic spontaneous urticaria: wheal attacks every day or intermittently, each time lasting no more than 24 hours, lasting more than 6 weeks.
3. Despite the use of H1 antihistamines, wheezing and itching occurred at least 6 consecutive weeks before enrollment.
4. Urticaria activity score (UAS) >= 16 on 7 days, pruritus score >= 8 on each week.
5. The diary card of patients was complete one week before randomization.
6. Sign the informed consent, voluntarily and agree to complete each step of this clinical study.
|
排除标准:
|
1. 排除标准包括明确诱因的慢性荨麻疹 (如物理性荨麻疹)。
2. 入组前30天因任何指征而接受 (每天,或者大于等于连续3个隔天)的全身糖皮质激素, 羟基氯奎因, 甲氨蝶呤, 环孢菌素, 环磷酰胺, 或静脉注射免疫球蛋白治疗。
3. 筛选前7天,随机分组前14天,接受过任何H2抗组胺药,白三烯受体拮抗剂,奥马珠单抗治疗。
4. 筛选前3天,H1抗组胺药超过许可剂量。
5. 合并有心脑血管、糖尿病、骨代谢异常等疾病或肝、肾疾病及造血系统等伴有严重的原发性疾病者;伴有系统性红斑狼疾等严重自身免疫性疾病者。
6. 除慢性荨麻疹以外的疾病,具有荨麻疹或血管性水肿症状,如荨麻疹血管炎、多形红斑、皮肤肥大细胞增多(色素性荨麻疹)和遗传性或获得性血管性水肿(如由于C1抑制剂缺乏)。
7. 寄生虫感染。
8. 与慢性瘙痒相关的可能会影响研究评估和治疗结果的皮肤病(如特应性皮炎、大疱性天疱疮、疱疹性皮炎、老年瘙痒等)。
9. 研究期间有生育需求,妊娠,哺乳期妇女。
10. 磁共振禁忌的患者。
11. 最近3个月内正在参与或参加过其他临床试验。
|
Exclusion criteria:
|
1. Exclusion criteria included chronic urticaria with definite cause (such as physical urticaria).
2. Systemic glucocorticoid, hydroxychloroquine, methotrexate, cyclosporine, cyclophosphamide, or intravenous immunoglobulin therapy for any indication (daily, or three consecutive alternate days) 30 days before enrollment.
3. 7 days before screening, 14 days before randomization, received any H2 antihistamines, leukotriene receptor antagonists, omazumab treatment.
4. Three days before screening, H1 antihistamines exceeded the permitted dose.
5. Patients with cardiovascular and cerebrovascular diseases, diabetes mellitus, abnormal bone metabolism, liver and kidney diseases, hematopoietic system and other serious primary diseases; patients with systemic lupus erythematosus and other serious autoimmune diseases.
6. Diseases other than chronic urticaria have symptoms of urticaria or angioedema, such as urticaria vasculitis, erythema multiforme, cutaneous mast cell hyperplasia (pigmented urticaria) and hereditary or acquired angioedema (e.g. due to lack of C1 inhibitors).
7. Parasite infection.
8. Chronic pruritus related skin diseases (such as atopic dermatitis, bullous pemphigus, herpetic dermatitis, senile pruritus, etc.) that may affect the evaluation and treatment results of the study.
9. Pregnant and lactating women with reproductive needs during the study period.
10. Patients with MRI contraindications.
11. Have participated in or participated in other clinical trials in the last three months.
|
研究实施时间:
Study execute time:
|
从From
2020-01-01
至To
2023-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-05-01
至To
2022-06-30
|